Markers for Guillain‐Barré syndrome with poor prognosis: a multi‐center study

• DOI: 10.1111/jns.12234
• Publication Date: 2017-08-18T09:46:36Z
• Authors: Yuko Yamagishi; Hidekazu Suzuki; Masahiro Sonoo; Satoshi Kuwabara; Takanori Yokota; Kyoichi Nomura; Atsuro Chiba; Ryuji Kaji; Takashi Kanda; Kenichi Kaida; Shu‐ichi Ikeda; Tatsuro Mutoh; Ryo Yamasaki; Hiroshi Takashima; Makoto Matsui; Kazutoshi Nishiyama; Gen Sobue; Susumu Kusunoki
• Keywords: Center (category theory)

Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), respiratory insufficiency (EGRIS), and increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of subtypes differ between Western countries Japan, usefulness these Japan or other remains unknown. We enrolled 177 Japanese patients with from 15 university hospitals retrospectively obtained mEGOS EGRIS for all ΔIgG status 79 them. High scores on admission day 7 were significantly associated poorer outcomes (unable to walk independently at 6 months). (≥5 points) increased risk mechanical ventilation. Patients <1,108 mg/dl had outcomes. suggest mEGOS, EGRIS, are clinically relevant Japan.